NGM Biopharmaceuticals Inc. (NASDAQ:NGM) changes shares on Friday trading session, with a change of -2.71% or -$0.61 shares. The trading starts at $22.62 and closed at $22.52 throughout the day. The trading session low price was $21.81 and day high was $23.79 on Friday, June 19. After the session, the Healthcare sector daily volume shifted to 0.57 million while its average volume is 336.91K. In other hand, the NGM market cap reached to $1.53B. While, its current target price is $21.91 according to WSJ.
Checking out the performance report which defines the increase or decrease of prices for a specific period. For the last 5 trading sessions, its performance is up 5.85% and up 7.56% for month. Its quarterly performance was 87.91% above, while its half year performance is up 13.70%. NGM yearly performance stood at positive 57.63% and rise 18.50% for year-to-date. Current recommendation for NGM Biopharmaceuticals Inc. is 1.60.
Earnings per share or EPS is an important financial measure, which defines the profitability of a company. NGM EPS (TTM) for 12-month is -0.81. EPS for this year is -64.70%, while for the next year its value is -1.33. Its EPS Q/Q reached -126.50%.
Let’s take a look on the analyst recommendations on NGM for the current month and previous month. For the current month, 7 of 7 analysts recommend stock as Buy while 0 as Sell, 0 as overweight, 0 as underweight and 0 as Hold. As compared with the previous month ratings, 0 analysts participate in stock recommendation. Out of 0, 0 rated it sell, 0 rated it as Buy and 0 as Hold Ratings. On the other hand, target price ranges from $26.00-$32.00. Average target price for NGM was reached at $29.71.
Svennilson Peter, RHO Capital Partners Inc and Blackrock Inc. are the top three holders in NGM Biopharmaceuticals Inc. (NGM) stock. On Mar 30, 2020, Svennilson Peter has 17.32 million shares which valued 213.59 million. On Mar 30, 2020, RHO Capital Partners Inc owned 3.77 million shares which valued at 46.44 million. On Mar 30, 2020, Blackrock Inc. has a total of 2.25 million shares which valued at 27.76 million. In the end, Blackrock Inc. have 3.30% shares outstanding of NGM Biopharmaceuticals Inc. (NGM) on Mar 30, 2020. The insider ownership moved to 1.60% and institutional holding shifted to 60.90%.
The company posted an EPS (TTM) of -0.81. According to the most recent quarter report on (Jun 2020), 7 analysts estimated an average EPS of -0.32, while -0.13 EPS posted a year ago period. Analyst Estimated EPS for NGM published in the report was -0.39–0.17 during the same period. Comparing with last year, the average estimated EPS was -0.13 which is higher than -0.28 which was posted for recent quarter EPS.
A brief look on simple moving average (SMA) that determines the market price can impact a market. The SMA for NGM rise 33.69% for period of 200 days. SMA for 50 days was 13.47% which is showing green signal, while SMA-20 was 4.70%. The moving average value for NGM Biopharmaceuticals Inc. (NGM) is 17.60 and 20.85 for 200 and 50 days respectively.
Let’s take a look on the insider transactions, in which multiple shareholders are showing interest in NGM stock. On Jun 15, CHEN JIN-LONG, Chief Scientific Officer, sold 25,000 trading shares at the cost of $21.65, which valued at 0.54 million. On May 15, Lieu Hsiao D, SVP, Chief Medical Officer, sold 1,562 shares at the cost of $22.00, with total shares of 182. On Apr 08, Svennilson Peter, Director, bought 112,602 shares at the cost of 14.95. After this transaction, Svennilson Peter total shares reached to 17,706,978 which valued at 1.68 million.